Introduction
Cold snare polypectomy (CSP) is widely used to treat small superficial non-ampullary duodenal epithelial tumors (SNADETs) due to an advantageous safety profile. Nonetheless, histopathological completeness of CSP, particularly the resection depth, remains debatable. Underwater cold snare polypectomy (UCSP) has been reported to achieve deeper resection in the colon, but its efficacy in the duodenum remains unclear.
Aims & Methods
This study aimed to evaluate the histopathological resection depth of UCSP for SNADETs ≤10 mm and compare it with conventional CSP. This single-center prospective study included patients who underwent UCSP between January 2023 and December 2025. Outcomes were compared with those of a historical CSP cohort between August 2016 and November 2023. The primary endpoint was the proportion of the area containing the muscularis mucosa. Secondary endpoints included muscularis mucosa length, submucosal tissue acquisition, submucosal thickness, R0 resection rate, adverse events, and recurrence at 3 months. Comparisons were adjusted using inverse probability of treatment weighting (IPTW). The study was approved by the Institutional Review Board of Nagasaki University Hospital (Approval No. 23121804).
Results
A total of 28 UCSP and 18 CSP lesions were analyzed, with comparable baseline characteristics (median age, 70 vs 67 years; median lesion size, 4.5 vs 4 mm). The proportion of the area containing the muscularis mucosa was significantly higher in the UCSP group (median 36.6% vs 8.6%, P < 0.001). Muscularis mucosa length (median 3.4 vs 2.1 mm, P = 0.014) and submucosal layer thickness (median 0.37 vs 0.06 mm, P < 0.001) were also greater with UCSP. Submucosal tissue acquisition was higher in the UCSP group (100% vs 50%, P < 0.001). The R0 resection rate was higher with UCSP (89.3% vs 61.1%, P = 0.033). No adverse events or recurrences were observed. IPTW analysis confirmed the advantage for the primary endpoint (ATE 21.93%, 95% CI 12.75–31.10).
| UCSP (n=28)
| CSP (n=18)
| p-value
| ATE (95% Cl)
| IPTW p-value
|
Rate of area containing the muscularis mucosa, median, % (IQR)
| 36.6 (16.4–55.1)
| 8.6 (4.0–18.0)
| <0.001
| 21.93 (12.75–31.10)
| <0.001
|
Length of muscularis mucosa, median, mm (IQR)
| 3.4 (2.6–4.8)
| 2.1 (1.1–3.3)
| 0.014
| 0.95 (0.21–1.69)
| 0.012
|
Presence of submucosal layer, n (%)
| 28 (100)
| 9 (50)
| <0.001
| 0.39 (0.19–0.60)
| <0.001
|
Submucosal layer thickness, median, mm (IQR)
| 0.37 (0.24–0.46)
| 0.06 (0–0.24)
| <0.001
| 0.20 (0.12–0.27)
| <0.001
|
R0 resection rate, n (%)
| 25 (89.3)
| 11 (61.1)
| 0.033
| 0.43 (0.21–0.65)
| <0.001
|
Table. Comparison of histopathological outcomes between UCSP and CSP.
ATE, average treatment effect; CI, confidence interval; IPTW, inverse probability of treatment weighting; IQR, interquartile range.
Propensity scores were calculated using age, sex, tumor size, tumor location, macroscopic type, and histological diagnosis.
Conclusion
UCSP achieved deeper histopathological resection than CSP while maintaining a favorable safety profile in SNADETs ≤10 mm, suggesting UCSP as an effective treatment option for small SNADETs.